First Time Loading...

Bio-Techne Corp
NASDAQ:TECH

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
NASDAQ:TECH
Watchlist
Price: 63.87 USD 1.93% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. [ Read More ]

The intrinsic value of one TECH stock under the Base Case scenario is 49.78 USD. Compared to the current market price of 63.87 USD, Bio-Techne Corp is Overvalued by 22%.

Key Points:
TECH Intrinsic Value
Base Case
49.78 USD
Overvaluation 22%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Bio-Techne Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling TECH stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Bio-Techne Corp

Provide an overview of the primary business activities
of Bio-Techne Corp.

What unique competitive advantages
does Bio-Techne Corp hold over its rivals?

What risks and challenges
does Bio-Techne Corp face in the near future?

Has there been any significant insider trading activity
in Bio-Techne Corp recently?

Summarize the latest earnings call
of Bio-Techne Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bio-Techne Corp.

Provide P/S
for Bio-Techne Corp.

Provide P/E
for Bio-Techne Corp.

Provide P/OCF
for Bio-Techne Corp.

Provide P/FCFE
for Bio-Techne Corp.

Provide P/B
for Bio-Techne Corp.

Provide EV/S
for Bio-Techne Corp.

Provide EV/GP
for Bio-Techne Corp.

Provide EV/EBITDA
for Bio-Techne Corp.

Provide EV/EBIT
for Bio-Techne Corp.

Provide EV/OCF
for Bio-Techne Corp.

Provide EV/FCFF
for Bio-Techne Corp.

Provide EV/IC
for Bio-Techne Corp.

Show me price targets
for Bio-Techne Corp made by professional analysts.

What are the Revenue projections
for Bio-Techne Corp?

How accurate were the past Revenue estimates
for Bio-Techne Corp?

What are the Net Income projections
for Bio-Techne Corp?

How accurate were the past Net Income estimates
for Bio-Techne Corp?

What are the EPS projections
for Bio-Techne Corp?

How accurate were the past EPS estimates
for Bio-Techne Corp?

What are the EBIT projections
for Bio-Techne Corp?

How accurate were the past EBIT estimates
for Bio-Techne Corp?

Compare the revenue forecasts
for Bio-Techne Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Bio-Techne Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bio-Techne Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bio-Techne Corp compared to its peers.

Compare the P/E ratios
of Bio-Techne Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Bio-Techne Corp with its peers.

Analyze the financial leverage
of Bio-Techne Corp compared to its main competitors.

Show all profitability ratios
for Bio-Techne Corp.

Provide ROE
for Bio-Techne Corp.

Provide ROA
for Bio-Techne Corp.

Provide ROIC
for Bio-Techne Corp.

Provide ROCE
for Bio-Techne Corp.

Provide Gross Margin
for Bio-Techne Corp.

Provide Operating Margin
for Bio-Techne Corp.

Provide Net Margin
for Bio-Techne Corp.

Provide FCF Margin
for Bio-Techne Corp.

Show all solvency ratios
for Bio-Techne Corp.

Provide D/E Ratio
for Bio-Techne Corp.

Provide D/A Ratio
for Bio-Techne Corp.

Provide Interest Coverage Ratio
for Bio-Techne Corp.

Provide Altman Z-Score Ratio
for Bio-Techne Corp.

Provide Quick Ratio
for Bio-Techne Corp.

Provide Current Ratio
for Bio-Techne Corp.

Provide Cash Ratio
for Bio-Techne Corp.

What is the historical Revenue growth
over the last 5 years for Bio-Techne Corp?

What is the historical Net Income growth
over the last 5 years for Bio-Techne Corp?

What is the current Free Cash Flow
of Bio-Techne Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bio-Techne Corp.

Financials

Balance Sheet Decomposition
Bio-Techne Corp

Current Assets 590.6m
Cash & Short-Term Investments 135.7m
Receivables 207.5m
Other Current Assets 247.5m
Non-Current Assets 2.1B
PP&E 335.1m
Intangibles 1.5B
Other Non-Current Assets 274.4m
Current Liabilities 135.2m
Accounts Payable 31.5m
Accrued Liabilities 62.8m
Other Current Liabilities 40.9m
Non-Current Liabilities 632m
Long-Term Debt 447m
Other Non-Current Liabilities 185m
Efficiency

Earnings Waterfall
Bio-Techne Corp

Revenue
1.1B USD
Cost of Revenue
-376.2m USD
Gross Profit
768.7m USD
Operating Expenses
-490.1m USD
Operating Income
278.6m USD
Other Expenses
-54.4m USD
Net Income
224.2m USD

Free Cash Flow Analysis
Bio-Techne Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

TECH Profitability Score
Profitability Due Diligence

Bio-Techne Corp's profitability score is 63/100. The higher the profitability score, the more profitable the company is.

63/100
Profitability
Score

Bio-Techne Corp's profitability score is 63/100. The higher the profitability score, the more profitable the company is.

TECH Solvency Score
Solvency Due Diligence

Bio-Techne Corp's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
87/100
Solvency
Score

Bio-Techne Corp's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TECH Price Targets Summary
Bio-Techne Corp

Wall Street analysts forecast TECH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TECH is 82.43 USD with a low forecast of 65.65 USD and a high forecast of 99.75 USD.

Lowest
Price Target
65.65 USD
3% Upside
Average
Price Target
82.43 USD
29% Upside
Highest
Price Target
99.75 USD
56% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

TECH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

TECH Price
Bio-Techne Corp

1M 1M
-7%
6M 6M
+4%
1Y 1Y
-18%
3Y 3Y
-41%
5Y 5Y
+34%
10Y 10Y
+205%
Annual Price Range
63.87
52w Low
52.83
52w High
89.42
Price Metrics
Average Annual Return 20.22%
Standard Deviation of Annual Returns 39.05%
Max Drawdown -60%
Shares Statistics
Market Capitalization 10B USD
Shares Outstanding 157 192 000
Percentage of Shares Shorted 4.4%

TECH Return Decomposition
Main factors of price return

What is price return decomposition?

TECH News

Other Videos

Company Profile

Bio-Techne Corp Logo
Bio-Techne Corp

Country

United States of America

Industry

Life Sciences Tools & Services

Market Cap

10B USD

Dividend Yield

0.49%

Description

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. The company is headquartered in Minneapolis, Minnesota and currently employs 2,600 full-time employees. The firm operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.

Contact

MINNESOTA
Minneapolis
614 McKinley Pl NE
+16123798854.0
https://www.bio-techne.com/

IPO

1989-02-09

Employees

2 600

Officers

CEO, President & Director
Mr. Kim Kelderman
Executive VP of Finance & CFO
Mr. James T. Hippel
Senior VP, General Counsel & Corporate Secretary
Mr. Shane Bohnen
Senior Advisor
Mr. Charles R. Kummeth
President of Protein Sciences Segment
Mr. William A. Geist
VP & CTO
Dr. Gary J. Latham Ph.D.
Show More
Senior Director of Investor Relations & Corporate Development
David Clair
Vice President of Sales and Marketing
Mr. Gerry Andros
Vice President of Corporate Development
Mr. Robert M. Gavin
Senior VP & Chief Human Resources Officer
Ms. Brenda S. Everson
Show Less

See Also

Discover More
What is the Intrinsic Value of one TECH stock?

The intrinsic value of one TECH stock under the Base Case scenario is 49.78 USD.

Is TECH stock undervalued or overvalued?

Compared to the current market price of 63.87 USD, Bio-Techne Corp is Overvalued by 22%.